Study of MS Progression in 361 Patients
In a study with 361 patients, 162 completed follow-ups, with 81 showing progression as defined by an increase in the Expanded Disability Status Scale. There were high dropout rates, with 97 at follow-up 1 and 102 at follow-up 2, and those who dropped out had worse initial clinical measures.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
Understanding MS progression is crucial for evaluating disease severity and treatment efficacy. However, high dropout rates may skew results, suggesting that observed progression might be underestimated in a general population.
What this does not prove
Less than half of participants completed the study, potentially biasing progression estimates. Dropouts exhibited worse initial measures, indicating that those more severely affected were underrepresented in the findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 361 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-14
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceSurvivor bias and disease progression in observational cohorts in multiple sclerosis. ↗DOI: 10.1177/13524585261490350
Supporting passages (5)
sample size361
publication date2026-10-14
primary endpointProgression was defined as an Expanded Disability Status Scale increase.
findingsRESULTS: One hundred and sixty-two patients with multiple sclerosis completed all follow-ups; 81 showed progression.
limitationsTitle: Survivor bias and disease progression in observational cohorts in multiple sclerosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.